Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer.
Saved in:
| Title: | Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer. |
|---|---|
| Authors: | LeVee A; Division of Hematology and Oncology, UCLA Geffen School of Medicine, Los Angeles, CA, USA.; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Kordic A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Ruel N; Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Mortimer J; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Kang I; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., McArthur H; Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, USA., Lechner MG; Division of Endocrinology, UCLA Geffen School of Medicine, Los Angeles, CA, USA., Tsai K; Department of Diabetes, Endocrinology and Metabolism, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. |
| Source: | The oncologist [Oncologist] 2025 Dec 01; Vol. 30 (12). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyaf371 |
